– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in...
– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative project with...
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company...
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology...
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology...
– Best quarterly financial results in history of the Company – Q1 2022 sales of $6,172,000 vs $4,702,000 in Q1 2021, a 31% increase – Operating profit...
PGX Technology continues to demonstrate ability to generate novel bioactive delivery systems for nutraceuticals, drug delivery and wound healing...
Accomplished business executive and attorney with diverse industry experience including over 20 years in life sciences and pharma with successful track...
– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro’s best sales performance in...
- Symrise to distribute and commercialize Ceapro’s high value active ingredients in the cosmetic market - - Supply and distribution agreement provides...